Table II.
The association of Cby protein expression with clinical features.
| Clinical features | Patients, n | Cby protein PR, % (n) | χ2 value | P-value |
|---|---|---|---|---|
| Sex | 2.747 | >0.05 | ||
| Male | 32 | 50 (16/32) | ||
| Female | 13 | 23.1 (3/13) | ||
| Age, years | 0.137 | >0.05 | ||
| ≤50 | 27 | 44.4 (12/27) | ||
| >50 | 18 | 38.9 (7/18) | ||
| T staging | 17.257 | <0.01 | ||
| 1/2 | 24 | 70.8 (17/24) | ||
| 3/4 | 21 | 9.5 (2/21) | ||
| Lymph node metastasis | 2.186 | >0.05 | ||
| N0 | 18 | 55.6 (10/18) | ||
| N1-3 | 27 | 33.3 (9/27) | ||
| Clinical staging | 30.097 | <0.01 | ||
| I/II | 19 | 89.5 (17/19) | ||
| III/IV | 26 | 7.7 (2/26) | ||
| Pathological classification | 0.228 | >0.05 | ||
| WHO I | 9 | 44.4 (4/9) | ||
| WHO II | 20 | 45.0 (9/20) | ||
| WHO III | 16 | 37.5 (6/16) |
Cby, Chibby; PR, positive rate; LNM, lymph node metastases; WHO I, keratinizing squamous cell carcinoma; WHO II, undifferentiated non-keratinizing carcinoma; WHO III, differentiated non-keratinizing carcinoma.